The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwAL 2025 | Selecting between options for induction therapy in patients with treatment-related AML
Tara Lin, MD, University of Kansas Medical Center, Kansas City, KS, discusses her approach to selecting between treatment options for patients with treatment-related acute myeloid leukemia (AML). Dr Lin references the CPX-351-301 trial (NCT01696084) as evidence for the use of CPX-351 over the 7+3 regimen for patients fit for intensive induction therapy. This interview took place at the 7th International Workshop on Acute Leukemias (iwAL 2025), held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So when I see a patient who has had a treatment-related AML, so someone who’s gotten chemotherapy for breast cancer or lymphoma or had a prior autologous transplant, if they are fit for intensive induction, which is a discussion all unto itself, I do favor the use of CPX-351 based on the data from the registrational 301 trial showing that patients with treatment-related AML had an overall survival of 12 months versus only six months for those who got seven and three...
So when I see a patient who has had a treatment-related AML, so someone who’s gotten chemotherapy for breast cancer or lymphoma or had a prior autologous transplant, if they are fit for intensive induction, which is a discussion all unto itself, I do favor the use of CPX-351 based on the data from the registrational 301 trial showing that patients with treatment-related AML had an overall survival of 12 months versus only six months for those who got seven and three. We don’t have that same kind of comparison for patients with HMA venetoclax, but if a patient is someone that I would not consider for an intensive induction, that’s when I would use HMA venetoclax even in the setting of a prior chemotherapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
